Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease

被引：0
作者：
Shiveena Bhatia
Manjinder Singh
Tanveer Singh
Varinder Singh
机构：
[1] Chitkara University,Chitkara College of Pharmacy
[2] Texas A &M University Health Science Centre,Department of Neuroscience and Experimental Therapeutics, College of Medicine
来源：
Neurochemical Research | 2023年 / 48卷
关键词：
PROTACs; Alzheimer’s disease; UPS machinery; Neurodegenerative disorders; Protein degradation; Dementia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Finding an effective cure for Alzheimer’s disease has eluded scientists despite intense research. The disease is a cause of suffering for millions of people worldwide and is characterized by dementia accompanied by cognitive and motor deficits, ultimately culminating in the death of the patient. The course of the disease progression has various underlying contributing pathways, with the first and foremost factor being the development and accumulation of aberrant and misfolded proteins exhibiting neurotoxic functions. The impairment of cellular clearance mechanisms adds to their accumulation, resulting in neuronal death. This is where the PROteolysis TArgeting Chimera (PROTAC) technology comes into play, bringing the UPS degradation machinery in the proximity of the target protein for initiating its degradation and clearing abnormal protein debris with unparalleled precision demonstrating an edge over traditional protein inhibitors in many respects. The technology is widely explored in cancer research and utilized in the treatment of various tumors and malignancies, and is now being applied in treating AD. This review explores the application of PROTAC technology in developing lead compounds for managing this deadly disease along with detailing the pieces of evidence justifying its utility and efficacy.
引用
收藏
页码：13 / 25
页数：12
相关论文
共 392 条
[31]  
Oddo S(2017)Proteasomal and autophagic degradation systems Annu Rev 32 431-807
[32]  
Zhang Y(2012)Modulating macroautophagy: a neuronal perspective Future Med Chem 38 265-7
[33]  
Chen X(2010)Selective degradation of p62 by autophagy Semin Immunopathol 9 1102-174
[34]  
Zhao Y(2010)The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy Mol Cell 43 38-8559
[35]  
Ponnusamy M(2007)Autophagosome formation: core machinery and adaptations Nat Cell Biol 87 797-1358
[36]  
Liu Y(2011)Autophagy failure in Alzheimer’s disease—locating the primary defect Neurobiol Dis 9 1-562
[37]  
Al Mamun A(2020)Autophagy dysfunction in Alzheimer’s disease: mechanistic insights and new therapeutic opportunities Biol Psychiatry 12 185-617
[38]  
Rahman MM(2019)Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer’s disease and mild cognitive impairment Sci Rep 6 AN20130044-123
[39]  
Zaman S(2018)Autophagic degradation deficit involved in sevoflurane-induced amyloid pathology and spatial learning impairment in APP/PS1 transgenic mice Front Cell Neurosci 64 162-11301
[40]  
Munira MS(2014)Accumulation of amyloid-like Aβ1–42 in AEL (autophagy–endosomal–lysosomal) vesicles: potential implications for plaque biogenesis ASN Neuro 51 e12427-114
12345678910